Acorda Therapeutics Announces Data on AMPYRA(TM) (dalfampridine) Presented at American Academy of Neurology Meeting
(Posted By: Josi Creek)
Responders to AMPYRA Treatment Showed Improvement in Average Walking Speed Compared to their Average Baseline for Up to 2.5 Years in Open-Label Studies
